Stay updated with breaking news from Alanh Auerbach. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2023. Unless otherwise stated, all comparisons are for the second quarter of 2023 compared to the second quarter of 2022.Product revenue, net consists...
Puma Biotechnology, Inc. (NASDAQ:PBYI – Free Report) CEO Alan H. Auerbach sold 60,698 shares of the stock in a transaction dated Monday, July 3rd. The shares were sold at an average price of $3.31, for a total value of $200,910.38. Following the completion of the sale, the chief executive officer now directly owns 6,978,343 shares […]
Puma Biotechnology, Inc. , a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone in metastatic... | June 4, 2023
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II study of alisertib plus paclitaxel versus paclitaxel alone (Clinicatrials.gov identifier NCT02187991) in metastatic hormone receptor positive (HR+) and...
Soligenix (NASDAQ:SNGX – Get Rating) and Puma Biotechnology (NASDAQ:PBYI – Get Rating) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, profitability, dividends, risk, institutional ownership, earnings and analyst recommendations. Risk & Volatility Soligenix has a beta of 1.74, indicating […]